ArticleUnited European gastroenterology journal2025
Target Trial Emulation of Beta-Blockers After Diagnosis of Colorectal Polyps-Beneficial in Women.
Article in United European gastroenterology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting β-Adrenergic Signaling in Colorectal Cancer: Molecular Mechanisms and Therapeutic Potential of β-Blockers.Cancers · 2026Review
- Old Drugs, New Opportunities: Advancing Cancer Care Through Repurposing.United European gastroenterology journal · 2026Article
- Target Trial Emulation of Beta-Blockers After Diagnosis of Colorectal Polyps-Beneficial in Women.United European gastroenterology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND AND
aimsBeta-blockers are successfully used to treat hemangioma and may decrease the proliferation of cancer cells. We hypothesized that individuals with colorectal polyps may also benefit from beta-blocker initiation.
methodsIndividuals diagnosed with their first colorectal polyp 2006-2016 in the nationwide Swedish ESPRESSO histopathology cohort aged 45-79 years without CRC were eligible. We excluded individuals with previous indications for beta-blocker (cerebrovascular disease, heart failure, aortic aneurysms, myocardial infarction) and individuals with contraindications for preventive beta-blocker initiation (COPD, dementia, liver cirrhosis, Charlson score > 5 or metastatic cancer). Using duplication and inverse probability weighting, we emulated a target trial of beta-blocker initiation within 2 years of the first polyp diagnosis. Main outcomes were incident CRC, CRC mortality, and all-cause mortality until 2019.
resultsIn total, 30,399 individuals met our inclusion criteria and were followed for a median of 8 years. Beta-blockers were initiated in 2083 (6.9%) eligible individuals. The 10-year cumulative incidence in initiators versus non-initiators was 5.8% versus 8.6% for CRC incidence, 0.9% versus 1.1% for CRC mortality. The corresponding fully adjusted hazard ratios (HRs) were 0.87 (95% confidence interval, 95% CI: 0.85-0.89) and 0.96 (0.83-1.09). CRC mortality was significantly reduced in women HR 0.78 (0.68-0.99) but not in men HR = 1.14 (0.80-4.46). Cumulative CRC mortality was 0.6% in initiating women versus. 1.1% in non-initiating women.
conclusionBeta-blocker initiation within 2 years of polyp diagnosis was linked to a lower CRC incidence for all subgroups, and a lower CRC mortality in women, indicating that beta-blocker initiation may improve long-term outcomes in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.